Determining the true burden of kidney stone disease

被引:0
|
作者
Charat Thongprayoon
Amy E. Krambeck
Andrew D. Rule
机构
[1] Division of Nephrology and Hypertension,Department of Urology
[2] Mayo Clinic,undefined
[3] Indiana University,undefined
[4] Division of Epidemiology,undefined
[5] Mayo Clinic,undefined
来源
Nature Reviews Nephrology | 2020年 / 16卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The incidence and prevalence of kidney stones have increased over the past four decades. However, the diagnosis of ‘kidney stone’ can range from an incidental asymptomatic finding of limited clinical significance to multiple painful episodes of ureteral obstruction with eventual kidney failure. Some general strategies may be useful to prevent the recurrence of kidney stones. In particular, greater attention to kidney stone classification, approaches to assessing the risk of recurrence and individualized prevention strategies may improve the clinical care of stone formers. Although there have been some advances in approaches to predicting the recurrence of kidney stones, notable challenges remain. Studies of kidney stone prevalence, incidence and recurrence have reported inconsistent findings, in part because of the lack of a standardized stone classification system. A kidney stone classification system based on practical and clinically useful measures of stone disease may help to improve both the study and clinical care of stone formers. Any future kidney stone classification system should be aimed at distinguishing asymptomatic from symptomatic stones, clinically diagnosed symptomatic stone episodes from self-reported symptomatic stone episodes, symptomatic stone episodes that are confirmed from those that are suspected, symptomatic recurrence from radiographic recurrence (that is, with radiographic evidence of a new stone, stone growth or stone disappearance from presumed passage) and determine stone composition based on mutually exclusive categories.
引用
收藏
页码:736 / 746
页数:10
相关论文
共 50 条
  • [41] Metabolic changes in kidney stone disease
    Xu, Zhenzhen
    Yao, Xiangyang
    Duan, Chen
    Liu, Haoran
    Xu, Hua
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] Prospects for proteomics in kidney stone disease
    Vinaiphat, Arada
    Thongboonkerd, Visith
    EXPERT REVIEW OF PROTEOMICS, 2017, 14 (03) : 185 - 187
  • [43] KIDNEY-STONE DISEASE OF ELKS
    LITVINOV, VF
    DOKLADY AKADEMII NAUK BELARUSI, 1975, 19 (03): : 274 - 275
  • [44] Transcription factors in kidney stone disease
    Stone, Louise
    NATURE REVIEWS UROLOGY, 2023, 20 (02) : 64 - 64
  • [45] Osteopontin and kidney stone disease.
    Tinkel-Vernon, HJ
    Osborne, C
    Simmonds, HA
    Yang, M
    Zerlanko, BJ
    Rittling, S
    Denhardt, DT
    Sahota, A
    Tischfield, JA
    AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (04) : 418 - 418
  • [46] Optimum Nutrition for Kidney Stone Disease
    Heilberg, Ita P.
    Goldfarb, David S.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2013, 20 (02) : 165 - 174
  • [47] Transcription factors in kidney stone disease
    Louise Stone
    Nature Reviews Urology, 2023, 20 : 64 - 64
  • [48] Proteomics in genetic kidney stone disease
    Langman, C. B.
    Vural, G.
    Brooks, E.
    Ballard, K.
    McDade, R.
    Miller, J.
    Dupont, F.
    Milliner, D.
    Hoppe, B.
    Salido, E.
    Cochat, P.
    PEDIATRIC NEPHROLOGY, 2011, 26 (09) : 1739 - 1740
  • [49] Familiality of kidney stone disease in Iceland
    Edvardsson, Vidar O.
    Palsson, Runolfur
    Indridason, Olafur S.
    Thorvaldsson, Sverrir
    Stefansson, Kari
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2009, 43 (05): : 420 - 424
  • [50] Pharmacologic Treatment of Kidney Stone Disease
    Eisner, Brian H.
    Goldfarb, David S.
    Pareek, Gyan
    UROLOGIC CLINICS OF NORTH AMERICA, 2013, 40 (01) : 21 - +